%0 Journal Article
%A Gounder, Mrinal
%A Abdul Razak, Albiruni R
%A Gilligan, Adrienne M
%A Leong, Hoyee
%A Ma, Xiwen
%A Somaiah, Neeta
%A Chawla, Sant P
%A Martin-Broto, Javier
%A Grignani, Giovanni
%A Schuetze, Scott M
%A Vincenzi, Bruno
%A Wagner, Andrew J
%A Chmielowski, Bartosz
%A Jones, Robin L
%A Shah, Jatin
%A Shacham, Sharon
%A Kauffman, Michael
%A Riedel, Richard F
%A Attia, Steven
%T Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.
%D 2021
%U http://hdl.handle.net/10668/17582
%X Objective: Compare health-related quality of life (HRQoL) of selinexor versus placebo in patients with dedifferentiated liposarcoma. Materials & methods: HRQoL was assessed at baseline and day 1 of each cycle using the European Organization for Research and Treatment of Cancer 30-item core quality of life questionnaire. Results were reported from baseline to day 169 (where exposure to treatment was maximized while maintaining adequate sample size). Results: Pain scores worsened for placebo versus selinexor across all postbaseline visits, although differences in HRQoL at some visits were not significant. Other domains did not exhibit significant differences between arms; however, scores in both arms deteriorated over time. Conclusion: Patients treated with selinexor reported lower rates and slower worsening of pain compared with patients who received placebo.
%K advanced liposarcoma
%K pain
%K patient-reported outcomes
%K progression-free survival
%K quality of life
%K selective inhibitor of nuclear export
%K selinexor
%~